Corrigendum to 'Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany'
- Resource Type
- article
- Source
- Breast, Vol 55, Iss , Pp 138-139 (2021)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 1532-3080